Insmed earnings selloff a buying opportunity, says H.C. Wainwright

H.C. Wainwright views the post-earnings selloff in shares of Insmed (INSM) as a buying opportunity. The “core Brinsupri launch thesis remains intact,” the analyst tells investors in a research note. The firm says that with the second full quarter of launch, Brinsupri is well positioned for a “strong and durable launch.” It keeps a Buy rating on the shares with a $220 price target